World first, as patient receives an implanted pump system to manage pleural effusions

Zurich, Switzerland: 5 November 2014 - Sequana Medical AG, a private Swiss medical device company with innovative fluid management technologies, today announced a world-first, as a patient at Hôpital Nord, Marseille, France, was implanted with a pleurapump system designed to manage chronic pleural effusions (recurrence of excess fluid which collects around the lungs). The patient is the first to be enrolled in the Company's ADEPT study, which will assess the feasibility of this new therapy for management of pleural effusions.

The pleurapump system is a fully implantable battery-powered pump system that automatically and continually moves chronic pleural effusions from the pleural space around the lungs to the bladder, where it is passed naturally from the body. The system is designed to manage fluid balance within the body which helps patients live more independently, improves patient quality of life and reduces health care costs.

More info on the press release or on Sequana Medical's website.


Next > EpiGaN is named in the 2014 Global Cleantech 100’s Ones to Watch List

Previous > Nexstim Plc successfully completes its Initial Public Offering - subscriptions reach € 15.3 million with final offer price of € 6.35 per share